Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Cabozantinib |
Indication/Tumor Type | renal carcinoma |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | renal carcinoma | not applicable | Cabozantinib | Phase II | Actionable | In a Phase II trial, renal cancer patients treated with Cabozantinib demonstrated a 28 % objective response rate, a 62 % stable disease rate, and a median progression free survival of 14.7 months (PMID: 23292795). | 23292795 |
PubMed Id | Reference Title | Details |
---|---|---|
(23292795) | Cabozantinib as a novel therapy for renal cell carcinoma. | Full reference... |